As targeted therapies against melanoma mainly consist of the combination of a BRAFV600 inhibitor and MEK inhibitor, but the development of resistance may apply to only one of these agents, we focus on resistance to trametinib, an inhibitor of MEK broadly used in anticancer therapy [27,28,29,30]. The gene discussed is MAP2K7; the disease is melanoma.